In animal studies, the SGLT2 inhibitor, empagliflozin (EMPA), has been shown to have protective effects on myocardial hypertrophy and diastolic function in mice with prediabetic metabolic syndrome [15]. The gene discussed is SLC5A2; the disease is cardiac hypertrophy.